x

Search for a clinical trial

* (*) mandatory field

An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia - FR

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Ongoing trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Boehringer ingelheim
  • Website
    • Phase : I - II
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - FR
  • ADDRESS: NOT PROVIDED - FR
  • FRANCE
  • More information
  • Phone  : -
  • Fax  : -
  • Sponsor of clinical trial

  • BOEHRINGER INGELHEIM
  • Boehringer Ingelheim
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Binger Stra▀e 173
  • 55216 INGELHEIM AM RHEIN
  • GERMANY
  • More information
  • Phone  : 49 (0)6132 77 0
  • Fax  : 49 (0)6132 72 0
  • Website
Last update: March 2017

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.